Touchstone Capital Inc. Invests $5.66 Million in Edwards Lifesciences Co. (NYSE:EW)

Touchstone Capital Inc. acquired a new stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 74,241 shares of the medical research company's stock, valued at approximately $5,661,000. Edwards Lifesciences makes up about 5.4% of Touchstone Capital Inc.'s portfolio, making the stock its 7th biggest holding.

Several other institutional investors have also added to or reduced their stakes in the stock. Castleview Partners LLC acquired a new stake in Edwards Lifesciences in the 1st quarter valued at $25,000. Compass Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $31,000. Jackson Grant Investment Advisers Inc. acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at $38,000. Janiczek Wealth Management LLC increased its stake in shares of Edwards Lifesciences by 108.6% during the 3rd quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company's stock worth $40,000 after purchasing an additional 303 shares during the last quarter. Finally, Sunbelt Securities Inc. acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth about $49,000. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 10,000 shares of the company's stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $75.67, for a total value of $756,700.00. Following the completion of the transaction, the vice president now directly owns 39,503 shares in the company, valued at approximately $2,989,192.01. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 14,500 shares of the company's stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $91.01, for a total value of $1,319,645.00. Following the completion of the transaction, the vice president now directly owns 39,503 shares in the company, valued at approximately $3,595,168.03. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 10,000 shares of the stock in a transaction on Friday, January 12th. The stock was sold at an average price of $75.67, for a total transaction of $756,700.00. Following the sale, the vice president now owns 39,503 shares of the company's stock, valued at $2,989,192.01. The disclosure for this sale can be found here. Insiders sold a total of 182,349 shares of company stock worth $15,334,555 in the last three months. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded up $0.41 on Friday, reaching $95.56. 4,007,477 shares of the stock were exchanged, compared to its average volume of 4,107,345. The firm's 50 day moving average is $86.32 and its 200-day moving average is $76.13. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. The firm has a market cap of $57.52 billion, a PE ratio of 41.55, a P/E/G ratio of 4.72 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.64. The business had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm's quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.64 EPS. As a group, analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on EW shares. Oppenheimer boosted their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an "outperform" rating in a research note on Monday, March 18th. Mizuho boosted their price objective on shares of Edwards Lifesciences from $85.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, February 7th. Royal Bank of Canada boosted their price objective on shares of Edwards Lifesciences from $82.00 to $95.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 7th. Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an "overweight" rating in a research note on Thursday, March 21st. Finally, Evercore ISI downgraded shares of Edwards Lifesciences from an "outperform" rating to an "in-line" rating and reduced their target price for the stock from $80.00 to $77.00 in a report on Thursday, January 4th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average target price of $88.80.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.